myoARRAY and TcLandscape Analysis for the Diagnosis of Inflammatory Myopathies (MYOARRAY)

This study has been completed.
Sponsor:
Collaborator:
Association Française contre les Myopathies (AFM), Paris
Information provided by (Responsible Party):
University Hospital, Rouen
ClinicalTrials.gov Identifier:
NCT00213629
First received: September 13, 2005
Last updated: February 14, 2012
Last verified: February 2012
  Purpose

The diagnosis of the different forms of inflammatory myopathies (polymyositis, dermatomyositis, inclusion-body myositis...) remains difficult which may lead to unappropriate patient care.

Objective 1 : to develop and evaluate the diagnostic value of a dedicated DNA-array (myoARRAY) for adult-onset muscular diseases with focus on inflammatory myopathies.

Objective 2 : to evaluate the diagnostic value of T cell repertoire (TcLand) analysis to distinguish different forms of inflammatory myopathies.


Condition Intervention
Polymyositis
Dermatomyositis
Other: transcriptome analysis
Other: T cell repertoire analysis

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Transcriptome Analysis Through a Dedicated Macro-array and TcLandscape Repertoire Analysis for Diagnosis of Myositis.

Resource links provided by NLM:


Further study details as provided by University Hospital, Rouen:

Primary Outcome Measures:
  • transcriptome [ Time Frame: at inclusion ] [ Designated as safety issue: No ]

Enrollment: 100
Study Start Date: November 2004
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
no arm
no arm
Other: transcriptome analysis
transcriptome analysis from muscle biopsy
Other: T cell repertoire analysis
blood T cell repertoire analysis

  Eligibility

Ages Eligible for Study:   18 Years to 76 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • indication of muscle biopsy for diagnostic purpose
  • written informed consent

Exclusion Criteria:

  • vasculitis
  • coagulation disorder, impossibility to perform muscle biopsy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00213629

Locations
France
University Hospital of Rouen
Rouen, Seine Maritime, France, 76000
Sponsors and Collaborators
University Hospital, Rouen
Association Française contre les Myopathies (AFM), Paris
Investigators
Principal Investigator: Olivier Boyer, MD, PhD University Hospital, Rouen
  More Information

No publications provided

Responsible Party: University Hospital, Rouen
ClinicalTrials.gov Identifier: NCT00213629     History of Changes
Other Study ID Numbers: 2003/094/HP
Study First Received: September 13, 2005
Last Updated: February 14, 2012
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Rouen:
myositis
cDNA arrays
Genes, T-Cell Receptor beta

Additional relevant MeSH terms:
Dermatomyositis
Myositis
Polymyositis
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Connective Tissue Diseases
Skin Diseases

ClinicalTrials.gov processed this record on July 24, 2014